Corbus Pharmaceuticals (CRBP) PT Lowered to $58 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts CRBP Hot Sheet
Price: $4.15 --0%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 12
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 12
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $58.00 (from $65.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Canada Goose (GOOS:CN) (GOOS) PT Lowered to Cdn$9 at Williams Trading
- AMD (AMD) PT Raised to $800 at Aletheia Capital, adds to Alpha Portfolio
- NXP Semiconductors NV (NXPI) PT Lowered to $313 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
